CClinicalTrials.gg
Sign In
CompletedNCT06163053Updated Jan 14, 2026

A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

An observational study in Cancer and Solid Tumors, sponsored by Bristol-Myers Squibb. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Bristol-Myers Squibb · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
49
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this observational study in France is to evaluate changes in satisfaction with care in participants with solid tumors who transitioned from receiving immunotherapy treatment in the hospital outpatient setting to receiving treatment at home

02

Conditions studied

  • Cancer
  • Solid Tumors

Browse trials for

03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 49 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.

Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants in France with solid tumors transitioning from receiving immunotherapy treatment in the hospital outpatient setting to receiving treatment at home

Inclusion criteria

  • Male or female ≥ 18 years old
  • Participants whose oncology specialist has already initiated treatment with immune checkpoint inhibitors (ICIs) in the outpatient hospital setting for an advanced solid tumor (as monotherapy or in combination) or as adjuvant therapy, in an indication approved and reimbursed in France
  • Participants whose oncology specialist has independently of the study defined their eligibility for hospital at home (HAH) before contacting the HAH unit for final admission
  • Participants who provide oral informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Participants who have expressed an opposition to their data collection
  • Participants under guardianship
  • Participants taking part in an interventional study for cancer treatment with at least one ICI as an investigational drug
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
49 participants (actual)
Target follow-up
24 Weeks
Patient registry
Yes

Groups and cohorts

  • Participants receiving immunotherapy at home

    Drug: Immunotherapy

Interventions

  • DrugImmunotherapy

    Immune checkpoint inhibitors in approved indications

06

What researchers measure

Primary outcomes

  1. Change in patient satisfaction on the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) when transitioning from Outpatient Hospital to Hospital at Home to receive immunotherapy

    Time frame: Participants follow up approximately 24 weeks after transition to treatment at home

07

Study locations

3 sites
  • CH Metropole Savoie
    Chambéry, 73011, France
  • CH Francois Quesnay
    Mantes-la-Jolie, 78200, France
  • CH de Pau
    Pau, 64046, France
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06163053
Lead sponsor
Bristol-Myers Squibb
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Aug 29, 2023
Primary completion
Jun 12, 2025
Completion
Jun 12, 2025
Last update
Jan 14, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

Bristol-Myers Squibb

Start the discussion